Thalidomide UK
  EMEA  
Home
Contact Us
About Us
Talidomida Espana
Our Committee
Our Founder/President
The History
Talk Thalidomide
The Drug Today
Medical Research
Campaign Info
Thalidomide Brands
The Drugs & Science
Compensation Info
Thalidomide Q&A
Thalidomide World Links
World of Thalidomide
What the Press Said
Freddie Musena Fund
Thalidomider Links
Vote Online
Website Rules

 

 

 

 

EMEA

European Medicines Agency (EMEA) is a decentralised body of the European Union with headquarters in London.

bullet Its main responsibility is the protection and promotion of public and animal health, through the evaluation and supervision of medicines for human and veterinary use. The EMEA coordinates the evaluation and supervision of medicinal products throughout the European Union. The Agency brings together the scientific resources of the 25 EU Member States in a network of 42 national competent authorities. It cooperates closely with international partners, reinforcing the EU contribution to global harmonisation.
bullet The EMEA is headed by the Executive Director and has a secretariat of about 360 staff members in 2004. The Management Board is the supervisory body of the EMEA, responsible, in particular, for budgetary matters.
bullet The EMEA began its activities in 1995, when the European system for authorising medicinal products was introduced, providing for a centralised and a mutual recognition procedure. The EMEA has a role in both, but is primarily involved in the centralised procedure. Where the centralised procedure is used, companies submit one single marketing authorisation application to the EMEA. A single evaluation is carried out through the Committee for Medicinal Products for Human Use (CHMP) or Committee for Medicinal Products for Veterinary Use (CVMP). If the relevant Committee concludes that quality, safety and efficacy of the medicinal product is sufficiently proven, it adopts a positive opinion. This is sent to the Commission to be transformed into a single market authorisation valid for the whole of the European Union.
bullet In 2001, the Committee on Orphan Medicinal Products (COMP) was established, charged with reviewing designation applications from persons or companies who intend to develop medicines for rare diseases (so-called ‘orphan drugs’). The Committee on Herbal Medicinal Products (HMPC) was established in 2004 and provides scientific opinions on traditional herbal medicines.
bullet A network of some 3,500 European experts underpins the scientific work of the EMEA and its committees.

 

 

 

 

 

 

 

 

 

 

© Thalidomide UK 2002. All rights reserved